Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Bettermann, K; Benesch, M; Weis, S; Haybaeck, J.
SUMOylation in carcinogenesis.
Cancer Lett. 2012; 316(2):113-125 Doi: 10.1016/j.canlet.2011.10.036
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Bettermann Kira
Haybäck Johannes
Co-Autor*innen der Med Uni Graz
Benesch Martin
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
SUMOylation is a post-translational modification characterized by covalent and reversible binding of small ubiquitin-like modifier (SUMO) to a target protein. In mammals, four different isoforms, termed SUMO-1, -2, -3 and -4 have been identified so far. SUMO proteins are critically involved in the modulation of nuclear organization and cell viability. Their expression is significantly increased in processes associated with carcinogenesis such as cell growth, differentiation, senescence, oxidative stress and apoptosis. Little is known about the role of SUMOylation in cancer development. Therefore the present review focuses on possible implications of SUMOylation in carcinogenesis highlighting its impact as an important regulatory cell cycle protein. Moreover, novel opportunities for therapeutic approaches are discussed. The differential expression levels, the target protein preferences and the function of the SUMO pathway in different cancer subtypes raises unexpected issues questioning our understanding of the implication of SUMO in carcinogenesis. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Cell Differentiation -
Cell Transformation, Neoplastic - metabolism
Humans -
Signal Transduction -
Small Ubiquitin-Related Modifier Proteins - metabolism
Sumoylation - physiology
Ubiquitin - genetics

Find related publications in this database (Keywords)
SUMO
Cancer
Ubiquitin
© Med Uni Graz Impressum